Patent application number | Description | Published |
20090035446 | Solid Solution Perforator Containing Drug Particle and/or Drug-Adsorbed Particles - A solid drug solution perforator containing drug particles and/or drug-adsorbed or loaded particles with an associated drug reservoir (SSPP system) are provided for delivering therapeutic, prophylactic and/or cosmetic compounds, diagnostics, and for nutrient delivery and drug targeting. For drug delivery, the SSPP system includes an active drug ingredient in particulate form or drug adsorbed on the particle surface in a matrix material that dissolves upon contact with a patient's body. In a preferred method of transdermal drug delivery, an SSPP system containing a drug-adsorbed microparticle penetrates into the epidermis or dermis, and the drug is released from the (dissolving) SSPP system perforator and desorbed from the particles. An additional drug is optionally delivered from a patch reservoir through skin pores created by insertion of the perforator Formulation and fabrication procedures for the SSPP and associated reservoir are also provided. An SSPP system can be fabricated with variety of shapes and dimensions. | 02-05-2009 |
20090060986 | Transdermal delivery systems - Disclosed are bupivacaine transdermal delivery systems, and related methods. | 03-05-2009 |
20100010031 | TRANSORAL DOSAGE FORMS COMPRISING SUFENTANIL AND NALOXONE - The invention pertains to methods that include administering to a subject a transoral dosage form comprising a pharmaceutical carrier and sufentanil, and maintaining a mean pH ranging from about 3.5 to about 5.5 during a dosing period after administration of the transoral dosage form as determined using an in vitro donor media test. Related dosage forms are also disclosed. Also disclosed are transoral dosage forms and related methods, wherein a transoral dosage form may comprise: (1) about 5 to about 1000 micrograms of sufentanil; (2) about 50 micrograms to about 100 milligrams of naloxone; and (3) acidifying material in an amount sufficient to provide a mean pH ranging from about 3.5 to about 5.5 during a dosing period after administration of the transoral dosage form as determined using an in vitro donor media test; wherein the dosing period begins no earlier than about 1 minute after administration of the transoral dosage form, and ends no later than about 120 minutes after administration of the transoral dosage form. | 01-14-2010 |
20110121486 | METHOD OF MANUFACTURING SOLID SOLUTION PEFORATOR PATCHES AND USES THEREOF - Methods for fabricating and manufacturing solid solution perforators (SSPs) using sharp metal or glass needles and/or subsequent molding and use are described. The methods entail making microneedles by various precision machining techniques and micromold structures from curable materials. Various designs of patch, cartridge and applicator are described. Also described are methods for adjusting the microneedle mechanical strength using formulation and/or post-drying processes. | 05-26-2011 |
20120193840 | METHOD OF MANUFACTURING SOLID SOLUTION PERFORATOR PATCHES - Provided are methods for fabricating and manufacturing solid solution perforators (SSPs) using sharp metal and subsequent molding and use. The methods entail making microneedles by precision machining techniques and micromold structures from plastic materials. Various designs of patch are described. | 08-02-2012 |
20130273139 | TRANSDERMAL DELIVERY SYSTEMS - Disclosed are bupivacaine transdermal delivery systems, and related methods. | 10-17-2013 |
20130317456 | Transdermal Delivery Systems - Disclosed are bupivacaine transdermal delivery systems, and related methods. | 11-28-2013 |
20140316333 | DISSOLVING SOLID SOLUTION PERFORATOR PATCH FOR MIGRAINE TREATMENT - A dissolving solid solution perforator (SSP) patch for oral cavity administration may include at least one perforator. The at least one perforator may contain a first drug and be configured to pierce an outside layer of an oral cavity for promptly delivering the first drug. The at least one perforator may penetrate an epithelium layer of the oral cavity and to deliver the antimigraine drug into blood vessels in a submucosa layer. | 10-23-2014 |